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Abstract: Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and 
more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a 
plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted 
approaches have been developed to extend survival of these patients, including antiangiogenic 
treatment. Vascular endothelial growth factor (VEGF) signaling pathway plays a dominant role 
in stimulating angiogenesis, which is the main process promoting tumor growth and metastasis. 
Bevacizumab (bev; Avastin®) is a recombinant humanized monoclonal antibody that neutralizes 
VEGF’s biologic activity through a steric blocking of its binding with VEGF receptor. Cur-
rently, bev is the only antiangiogenic agent approved for the first-line treatment of advanced 
or recurrent nonsquamous NSCLC in “bev-eligible” patients. The ineligibility to receive bev 
is related to its toxicity. In the pivotal trials of bev in NSCLC, fatal bleeding events including 
pulmonary hemorrhage were observed with rates higher in the chemotherapy-plus-bev group. 
Therefore, in order to reduce the incidence of severe pulmonary hemorrhage, numerous exclusion 
criteria have been characteristically applied for bev such as central tumor localization or tumor 
cavitation, use of anticoagulant therapy, presence of brain metastases, age of patients (elderly). 
Subsequent studies designed to evaluate the safety of bev have demonstrated that this agent is 
safe and well tolerated even in those patients subpopulations excluded from pivotal trials. This 
review outlines the current state-of-the-art on bev use in advanced NSCLC. It also describes 
patient selection and future perspectives on this antiangiogenic agent.
Keywords: bevacizumab, nonsquamous NSCLC, eligibility, safety, subpopulations
Introduction
Lung cancer is the most common cause of cancer-related mortality worldwide. Non-
small-cell lung cancer (NSCLC) represents about 85% of all lung cancer cases;1 the 
majority of NSCLC patients present with advanced-stage disease at diagnosis, and 
even if platinum-based doublet chemotherapy has improved the outcome of these 
patients, prognosis remains poor with a median survival time that does not exceed 10 
months.2 Therefore, in last decade novel targeted therapies have been developed. In 
2015, two immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), 
nivolumab and pembrolizumab, were approved for second-line therapy of NSCLC.3–6 
In 2016, another checkpoint inhibitor targeting program death-ligand 1 (PD-L1), 
atezolizumab, was approved for the same indication.7 Moreover, pembrolizumab also 
received approval in 2016 for first-line NSCLC treatment in patients with high PD-
L1-expressing tumors.8
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Angiogenesis inhibition is regarded another attractive 
therapeutic strategy for patients with NSCLC. In 1971, 
Folkman9 first suggested that tumor growth was dependent 
on angiogenesis, a complex process in which new blood 
vessels form out of preexisting capillaries; the development 
of hypoxic regions in the tumor promotes the production of 
proangiogenic factors. The vascular endothelial growth factor 
(VEGF) signaling pathway plays a dominant role in stimulat-
ing tumor angiogenesis.10 VEGF is overexpressed by most of 
solid tumors, and circulating levels of VEGF are elevated in 
many cancers, including lung cancer.11 These findings have 
given rise to the development of agents that block the VEGF 
pathway to limit tumor angiogenesis. Bevacizumab (bev, 
Avastin) is a recombinant, humanized monoclonal antibody 
that blocks VEGF.12 The Eastern Cooperative Oncology 
Group (ECOG) 4599 study compared the efficacy of car-
boplatin (carbo)/paclitaxel with or without bev in patients 
with advanced nonsquamous NSCLC.13 The addition of 
bev to paclitaxel and carbo has significantly improved the 
median overall and progression-free survival (PFS), marking 
the beginning of a new paradigm for the first-line treatment 
of advanced or metastatic NSCLC with nonsquamous cell 
histology in appropriately selected patients.
This review summarizes current data and future perspec-
tives on bev in NSCLC. It also describes evidences of its good 
safety profile in patient subpopulations previously considered 
ineligible for bev, underlining that the selection of patients 
able to receive bev is currently based only on two valid eligi-
bility criteria (NSCLC with nonsquamous histology and no 
history of clinically significant hemoptysis), considering the 
lack of valid biomarkers predictive of response to treatment 
with antiangiogenic therapy.
The role of tumor angiogenesis in 
NSCLC
Tumor growth and spread is dependent on the formation of 
new blood vessels out of preexisting capillaries;9,14 this pro-
cess, termed tumor angiogenesis, is largely mediated by the 
hypoxia-inducible factor (HIF)-1α which promotes transcrip-
tion of proangiogenic genes encoding proteins such as VEGF, 
basic fibroblast growth factor, angiopoietins, interleukin-8, 
and placental growth factor, under hypoxic conditions.15,16 
The overexpression of these proangiogenic factors stimulates 
resident endothelial cells to proliferate and migrate to form 
new capillary tubes.17,18 Bone-marrow-derived angiogenic 
cells are also recruited by tumor-associated stroma.19
The VEGF signaling pathway plays a dominant role in 
tumor angiogenesis. Its consists of five ligands (VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, and placental growth fac-
tor) and three VEGF tyrosine kinase receptors (VEGFR-1, 
VEGFR-2, and VEGFR-3). VEGFR-2 is the major mediator 
of VEGF-driven responses in endothelial cells.20 VEGF is 
overexpressed by a majority of solid tumors, and circulat-
ing levels of VEGF are elevated in many cancer patients, 
including those with lung cancer.11 It has been demonstrated 
that levels of VEGF correlate significantly with increased 
angiogenesis, poor prognosis, and lymph node metastasis 
in patients with NSCLC.21–25 Furthermore, Chen et al26 
have found that microvessel density, an indirect measure of 
angiogenesis, was higher in NSCLC tumor specimens from 
patients with advanced-stage than those with early-stage 
NSCLC, and it was also higher in patients with lymph node 
metastases than in those with no metastases. In addition, in 
a recent paper analyzing the role VEGFR2 expression in 
NSCLC cells lines, it has been shown that VEGF-dependent 
VEGFR2 activation was relevant in a subset of NSCLC cells 
and was associated with increased tumor cell proliferation.27
Currently, the most established approach for limiting 
tumor angiogenesis is blockade of the VEGF pathway using 
monoclonal antibodies or tyrosine kinase inhibitors.
bev in the treatment of NSCLC
bev is a recombinant humanized monoclonal IgG1 antibody 
comprising amino acid sequences which are about 93% 
human and 7% murine. It has high affinity in binding with 
all VEGF-A isoforms circulating in blood and neutralizes 
VEGF’s biologic activity through a steric blocking of its 
binding with VEGFR.
bev was approved for first-line treatment of bev-eligible 
patients with advanced nonsquamous NSCLC in combination 
with chemotherapy according to results of two Phase III tri-
als (Table 1). In the randomized Phase III trial ECOG 4599, 
878 patients with recurrent or advanced NSCLC (stage IIIB 
or IV) were randomized to receive carbo/paclitaxel with 
or without bev.13 Chemotherapy was administered every 3 
weeks for six cycles and bev was administered at 15 mg/
kg every 3 weeks until evidence of disease progression or 
unacceptable toxicity. Patients with squamous-cell tumors, 
brain metastases, clinically significant hemoptysis, or 
inadequate organ function or performance status ECOG 
>1 were excluded. Improvement of overall survival (OS), 
PFS and objective response rate (ORR) were observed for 
the combination of bev and chemotherapy. Specifically, the 
median survival was 12.3 months in patients treated with 
chemotherapy plus bev, as compared with 10.3 months in 
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0.79; p=0.003). The median PFS in the two groups was 6.2 
and 4.5 months, respectively (HR for disease progression, 
0.66; p<0.001), with corresponding response rates of 35% 
and 15% (p<0.001). Rates of clinically significant bleeding 
were 4.4% and 0.7%, respectively (p<0.001). There were 15 
treatment-related deaths in the chemotherapy-plus-bev group, 
including 5 from pulmonary hemorrhage.
In the randomized, placebo-controlled, Phase III trial Avas-
tin in Lung Cancer (AVAiL), 1,043 patients with advanced 
(stage IIIB, with supraclavicular lymph node metastasis or 
malignant pleural or pericardial effusion, or stage IV) or 
recurrent nonsquamous NSCLC were randomized to receive 
cisplatin (cis) and gemcitabine (gem) for up to six cycles 
plus low-dose bev (7.5 mg/kg), high-dose bev (15 mg/kg), or 
placebo every 3 weeks until disease progression.28 PFS was 
significantly prolonged with both doses of bev; the HRs for 
PFS were 0.75 (median PFS, 6.7 vs 6.1 months for placebo; 
p=0.003) in the low-dose group and 0.82 (median PFS, 6.5 
vs 6.1 months for placebo; p=0.03) in the high-dose group 
compared with placebo. ORRs were 20.1%, 34.1%, and 
30.4% for placebo, low-dose bev, and high-dose bev plus cis 
and gem, respectively. No significant difference in OS was 
observed, possibly because of high use of efficacious second-
line therapies.29 The rates of ≥ grade 3 hypertension, vomiting, 
neutropenia, bleeding, and proteinuria were modestly higher 
in the bev arms than in the placebo arm.
Analyzing the results of five randomized clinical trials 
(2,252 patients) comparing platinum-based chemotherapy 
doublets with or without bev in the first-line setting, Lima et 
al2 showed that the addition of bev to chemotherapy resulted 
in a significant improvement in both PFS (absolute benefit 
of 1.4 months in median) and response rate (RR) (absolute 
difference of 16%). Moreover, it has been also observed that 
there is a small homogeneous but significant OS improvement 
with an 11% reduction in risk of death, but with an estimated 
absolute benefit of less than 1 month in median survival.
The randomized, open-label, Phase III PRONOUNCE 
trial compared the efficacy and safety of pemetrexed + carbo 
followed by pemetrexed (Pem + Cb) with paclitaxel + carbo 
+ bev followed by bev (Pac + Cb + Bev) in patients with 
advanced nonsquamous NSCLC. The primary endpoint was 
PFS without grade 4 adverse events (G4PFS). Secondary 
endpoints included OS, PFS, RR, safety, and tolerability. Pem 
+ Cb did not produce significantly better G4PFS compared 
with Pac + Cb + Bev. Pem + Cb was not superior in PFS, OS, 
or ORR compared with Pac + Cb + Bev. Both regimens were 
well tolerated, although toxicity profiles differed.30
The emerging role of pemetrexed in treatment of non-
squamous NSCLC has aroused great interest in evaluating 
this agent in combination with bev. In the Phase III POINT-
BREAK trial, 939 patients were randomized to receive 
pemetrexed– carbo –bev, followed by pemetrexed plus bev 
in maintenance therapy or paclitaxel– carbo –bev followed 
by maintenance therapy with bev alone.31 PFS was statisti-
cally significantly longer for pemetrexed– carbo –bev than 
for paclitaxel– carbo –bev group (6.0 vs 5.6 months; HR, 
Table 1 Pivotal Phase III studies of bev in NSCLC: ECOG4599 and AVAiL
 ECOG 459913 AVAiL28
Eligibility criteria 
Diagnoses Stage IIIB, IV, or recurrent Stage IIIB, IV, or recurrent
Histology No predominantly squamous-cell cancer Only nonsquamous NSCLC
Age ≥18 years ≥18 years
Performance Status ECOG 0–1 ECOG 0–1
Main exclusion criteria – Significant hemoptysis 
– CNS metastases
– Hemorrhagic diathesis 
– Coagulopathy
– Therapeutic anticoagulation
– Use of aspirin
– Uncontrolled hypertension
– Significant hemoptysis 
– CNS metastases
–  History of thrombotic or hemorrhagic disorders
– Therapeutic anticoagulation
– Use of aspirin
– Uncontrolled hypertension
– Tumors invading or abutting
major blood vessels
Treatment arms Arm 1: bev + carbo + pac
Arm 2: carbo + pac
Arm 1: cis + gem + bev 7.5 mg/kg
Arm 2: cis + gem + bev 15 mg/kg
Arm 3: cis + gem + placebo
Primary endpoint OS PFS
Results Improvement in OS, PFS, ORR with bev Improvement in PFS and ORR with both doses of bev
No significant difference in OS
Abbreviations: bev, bevacizumab; carbo, carboplatin; cis, cisplatin; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; gem, gemcitabine; NSCLC, 



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





0.83; 95% confidence interval [CI], 0.71–0.96; p=0.012). 
Median PFS for the maintenance population was 8.6 months 
for pemetrexed– carbo –bev and 6.9 months for paclitaxel– 
carbo –bev groups. However, improvements in PFS did not 
translate into an OS advantage.
In the Phase III AVAPERL trial, 376 patients received 
four cycles of chemotherapy with cis, pemetrexed, and bev; 
those achieving response or stable disease were randomly 
assigned to maintenance therapy with bev or bev plus peme-
trexed. A significant PFS benefit was associated with bev plus 
pemetrexed maintenance compared with bev alone, and the 
combination was well tolerated.32 However, this study had 
some limitations that should be considered. First, survival 
data were based on selected patients who were eligible for 
bev and maintenance therapy. Second, there was no arm with 
pemetrexed alone as maintenance therapy.
Recently, treatment with dose-dense pemetrexed, gem, 
and bev demonstrated promising efficacy and manageable 
safety profile in patients with untreated advanced NSCLC.33
Several trials have been designed to define bev’s role in 
maintenance beyond progression and in an adjuvant setting. 
Nadler et al34 have retrospectively analyzed US Oncology 
network’s electronic medical records, dividing patients with 
advanced nonsquamous NSCLC treated from July 2006 
through June 2008, in two cohorts based on whether or 
not they received bev monotherapy to progression (BTP) 
after completion of first-line chemotherapy plus bev. From 
the total 498 patients, 403 received first-line chemotherapy 
plus bev: 154 received BTP, 249 did not. Longer PFS and 
OS times were observed in patients who received BTP than 
in those who received no BTP (median OS, 20.9 months 
vs 10.2 months; median PFS, 10.3 months vs 6.5 months). 
Therefore, continued VEGF suppression led to more favor-
able clinical outcomes. According to promising results of 
this retrospective analysis, the multicenter, open-label, ran-
domized, Phase IIIb AvaALL trial has randomized patients 
with advanced nonsquamous NSCLC whose disease has 
progressed after four to six cycles of first-line treatment 
with bev plus a platinum-based doublet and a minimum of 
two cycles of bev (monotherapy) maintenance treatment 
to standard second-line therapy (pemetrexed, docetaxel, or 
erlotinib) with or without bev. The primary endpoint was OS. 
Secondary endpoints included the 6-month, 12-month, and 
18-month OS rates, PFS, and time to progression at second 
and third progressive disease, response rate, disease control 
rates, and duration of response at second and third progres-
sive disease. The study has been completed, but results are 
not yet available.35
The ECOG E1505 study is currently assessing if adju-
vant chemotherapy is more effective with or without bev 
in treating patients with completely resected stage IB–IIIA 
NSCLC.36
About 20% of advanced NSCLC cases harbors somatic 
mutations in the tyrosine kinase domain of EGFR gene. 
In these patients, the standard first-line treatments are the 
EGFR-tyrosine kinase inhibitors, such as gefitinib, erlotinib, 
or afatinib. Most of these patients develop resistance and 
relapse within about 1 year of initiation of an EGFR-tyrosine 
kinase inhibitor. Consequently, it is important to develop new 
combination strategies to delay this resistance. Preclinical data 
have showed that EGFR and VEGF share a common down-
stream pathway, suggesting the important role of VEGF in the 
resistance to EGFR blockade. The combination of erlotinib 
and bev showed very interesting clinical results. The JO25567 
study is an open-label, randomized, multicenter, Phase II study 
that was conducted in Japan in order to assess the efficacy 
and safety of the combination of erlotinib and bev compared 
with erlotinib alone as first-line regimen in patients with non-
squamous NSCLC with activating EGFR mutation-positive 
disease. Median PFS (primary endpoint) was 16 months 
with erlotinib plus bev and 9.7 months with erlotinib alone 
(HR 0.54, 95% CI, 0.36–0.79; log-rank test p=0.0015);37 the 
BELIEF study (bev and ErLotinib In EGFR Mut + NSCLC) 
is the European ongoing equivalent clinical trial.38
A randomized, double-blind, placebo-controlled Phase III 
study (ATLAS) enrolled 1,157 patients with NSCLC (stage 
IIIB with malignant pleural effusion, stage IV, or recurrent) to 
receive maintenance bev every 3 weeks with or without erlo-
tinib after four cycles of platinum-based chemotherapy plus 
bev.39 The addition of erlotinib to bev significantly improved 
PFS but not OS. Moreover, during the postchemotherapy 
phase, there were more adverse events (AEs) overall, more 
grade 3 and 4 AEs (mainly rash and diarrhea), more serious 
AEs, and more AEs leading to erlotinib/placebo discontinu-
ation in the bev/erlotinib arm than the bev/placebo arm. A 
second randomized Phase III trial (the Bevacizumab/Tarceva 
(BeTa) lung trial) evaluated the addition of erlotinib to bev as 
second-line therapy in patients with recurrent or refractory 
NSCLC.40 The combination therapy significantly improved 
PFS (3.4 vs 1.7 months; HR, 0.62, 95% CI, 0.52–0.75) and 
elevated the disease control rate (45% vs 34%) compared 
with erlotinib alone. However, there was no significant dif-
ference in OS between the two groups (9.3 vs 9.2 months; 
HR, 0.97, 95% CI, 0.80–1.18; p=0.758). In the BeTa trial, 
355 (56%) patients were screened for EGFR mutations, and 
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the Erl group). Although the subgroup analysis data indicated 
a benefit in favor of patients with mutant EGFR compared 
with those with wild-type EGFR, the difference did not reach 
significance (p=0.1826). The ongoing randomized Phase III 
BEVERLY trial is evaluating if the first-line combination of 
erlotinib plus bev is better in terms of PFS than erlotinib alone 
in 200 Caucasian patients with NSCLC harboring activating 
EGFR mutations.41 The abovementioned randomized trials are 
summarized in Table 2.
Patient selection and future 
perspectives
The use of bevis indicated in selected patients only, because of 
its toxicity. Generally in subjects with NSCLC, it is safe and 
well tolerated.42–46 The most common AEs are hypertension, 
proteinuria, and epistaxis. Infrequent serious AEs include 
neutropenia complications, thromboembolic events, and 
pulmonary hemorrhage.
Hypertension appears to be dose dependent and related 
to increased peripheral vascular resistance induced by micro-
capillary rarefaction due to the inhibition of proangiogenic 
factors stimulating resident endothelial cells to proliferate 
and migrate to form new capillary tubes.47 Another potential 
pathogenetic mechanism may be decreased production of 
nitric oxide induced by bev. Decreased serum levels of nitric 
oxide cause constriction of the vasculature and a reduction 
in sodium ion renal excretion, leading to increased blood 
pressure.48
Bleeding in bev-treated patients may be related to inhibi-
tion of the endothelial repair processes mediated by VEGF 
and tumor erosion of vessels.
In order to reduce the incidence of severe hemorrhage, the 
first randomized clinical trials of bev in NSCLC excluded: 1) 
subjects with squamous histology; 2) subjects with significant 
hemoptysis; 3) subjects with tumors invading or abutting 
major blood vessels or with central tumor localization or 
with tumor cavitation, based on a radiological assessment; 
4) subjects with hemorrhagic disorders or in treatment with 
anticoagulant therapy; 5) subjects with brain metastases; 
6) subjects with ECOG>1; and 7) elderly patients (age ≥75 
years). In these last couple of years, the scientific community 
is speculating if some of these exclusion criteria for bev could 
be too precautionary or scientifically not so much valid, lead-
ing clinicians to inappropriately avoiding the use of bev in 
patients who might benefit from it.49,50
No statistically significant association was found between 
baseline or on-treatment cavitation tumor and severe pul-
monary hemorrhage incidence in bev-treated patients.50 
Similarly, central tumor location has not been shown to be a 
consistent predictive factor for severe pulmonary hemorrhage 
in these patients.51,52
Major blood vessel infiltration and bronchial vessel 
infiltration, encasement, and abutting may predict pulmo-
nary hemorrhage. However, their valuation is an individual 
assessment, and divergence between trained observers may 
occur even when radiological criteria are standardized. In 
Table 2 Randomized Phase III trials of bev in NSCLC
Study name Treatment arms Total pts (n)
Pts (n) arm 1
Pts (n) arm 2
Outcomes Safety
ECOG 459913 Arm 1: bev + carbo + pac




Improvement in OS, PFS, ORR with bev
HR (95% CI) for OS =0.79 (0.67 to 0.92); 
p=0.003 
HR (95% CI) for PFS =0.66 (0.57 to 0.77); 
p<0.001 
ORR: 15 % (arm 1) vs 35% (arm 2) 
(p<0.001)
Rates of significant bleeding: 
4.4% (arm 1) vs 0.7% 
(arm 2)
15 treatment-related deaths 
with bev (5 from pulmonary 
hemorrhage)
AVAiL28 Arm 1: cis + gem + bev 
7.5 mg/kg
Arm 2: cis + gem + bev 
15 mg/kg





Improvement in PFS and ORR with both 
doses of bev. Limited follow-up for OS 
analysis
HR (95% CI) for PFS arm 1=0.75 (0.62 to 
0.91); p=0.003
HR (95% CI) for PFS arm 2=0.82 (0.68 to 
0.98); p=0.03
ORR: 20.1% (arm 3) vs 34.1% (arm 1, 
p<0.0001) vs 30.4% (arm 2, p=0.0023) 
Similar incidence of grade 3 
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Study name Treatment arms Total pts (n)
Pts (n) arm 1
Pts (n) arm 2
Outcomes Safety
PRONOUNCE30 Arm 1: pem + carbo followed 
by pem maintenance
Arm 2: pac + carbo + bev 




Similar PFS, OS, and ORR
HR (95% CI) for PFS =1.06 (0.84 to 1.35); 
p=0.610
HR (95% CI) for OS =1.07 (0.83 to 1.36); 
p=0.615
ORR: 23.6% arm 1 vs 27.4% arm 2 
(p=0.414)
Tolerated but differed in 
their toxicity profiles 
POINTBREAK31 Arm 1: pem +carbo + bev 
followed by pem + bev 
maintenance
Arm 2: pac + carbo + bev 




Improvement in PFS with arm 1 
No significant difference in OS
HR (95% CI) for PFS =0.83 (0.71 to 0.96); 
p=0.012
HR (95% CI) for OS =1.00 (0.86 to 1.16); 
p=0.949
Tolerated but differed in 
their toxicity profiles
AVAPERL32 bev + cis + pem (induction)
if response or stable disease
arm 1: bev maintenance 




Improvement in PFS with arm 2
HR (95% CI) for PFS from random 
assignment =0.48 (0.35 to 0.66); p<0.001
OS from random assignment: 12.8 months 
(arm 1), it was not yet reached in arm 2.
No new safety signals were 
observed
AvaALL35 Progressive disease on first-line 
treatment with 4–6 cycles 
of bev + platinum-doublet 
and at least 2 cycles of bev 
maintenance:
Arm 1: bev + standard-of-
care (erlo or doce or pem) as 
second-line treatment
Arm 2: Standard of care (erlo 
or doce or pem) as second-line 
treatment
487 Results are not yet available Results are not yet available
ECOG E150536 Arm 1: adjuvant chemotherapy 
+ bev
Arm 2: adjuvant chemotherapy
_ This study is ongoing, but not recruiting 
participants
_
ATLAS39 Bev + platinum-doublet 
(induction)
Arm 1: bev maintenance




Improvement in PFS but not in OS
HR (95% CI) for PFS from random 
assignment =0.708 (0.580 to 0.864); 
p<0.001
HR (95% CI) for OS from random 
assignment =0.917 (0.698 to 1.205); 
p=0.5341
Higher degree of toxicity 
with arm 2
BeTa40 As second-line therapy:
Arm 1: erlo + bev




PFS and DCR seem to be better in arm 1 
but they cannot be defined as significant 
No significant difference in OS
HR (95% CI) for OS =0.97 (0.80 to 1.18); 
p=0.7583
HR (95% CI) for PFS =0.62 (0.52 to 0.75)
DCR: 45% (arm 1) vs 34% (arm 2) 
Mild toxicity with arm 1
BEVERLY41 As first-line therapy:
Arm 1: erlo + bev 
Arm 2: erlo + placebo
_ This study is currently recruiting 
participants.
_
Abbreviations: AE, adverse event; bev, bevacizumab; carbo, carboplatin; CI, confidence interval; cis, cisplatin; DCR, disease control rate; gem, gemcitabine; HR, hazard ratio; 
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particular, in the retrospective multicenter study of Barlesi 
et al,53 discordance in bev’s eligibility decisions among 
radiologists and oncologists based on 150 chest computed 
tomography scans from patients with central NSCLC tumors 
has been demonstrated.
Several studies evaluated safety of bev in patients with 
NSCLC and brain metastases. In the Phase II PASSPORT 
trial, addition of bev to various chemotherapy agents or erlo-
tinib in patients with NSCLC and treated brain metastases 
was found to be safe and related to a low incidence of central 
nervous system (CNS) hemorrhage.45 The ATLAS and BeTa 
trials also included patients with treated brain metastases 
and recorded a low rate of CNS hemorrhage, similarly.39,40
Besse et al54 conducted a retrospective exploratory analy-
sis using datasets from 17 clinical trials to assess the risk of 
cerebral hemorrhage in patients with brain metastases treated 
with bev for various solid tumors. The results of this study 
suggested that patients with brain metastases from advanced/
metastatic breast cancer, NSCLC, renal, and colorectal cancer 
should not be generally excluded from bev therapy because 
they present similar risk of developing cerebral hemorrhage, 
independent of bev therapy.
Recruiting subpopulations either excluded or under-
represented in clinical trials of bev in NSCLC (elderly aged 
≥75, patients with ECOG ≥2, and/or patients receiving 
full-dose anticoagulation therapy), the Phase IV SAiL trial 
and observational ARIES registry have shown that severe 
hemorrhage incidence is low and similar to that in Phase III 
trials patients.42,55 The observational cohort study ARIES also 
showed that none of the 67 patients with brain metastasis at 
baseline developed CNS hemorrhage.55
Recently, analyzing the efficacy and safety of bev, peme-
trexed, and carbo as induction therapy, followed by mainte-
nance therapy with bev plus pemetrexed in nonsquamous 
NSCLC patients with or without brain metastases, Stefanou 
et al56 concluded that this regimen was effective and well 
tolerated in advanced NSCLC, whether brain metastases 
were present or not.
A cost analysis of pemetrexed–platinum with mainte-
nance vs paclitaxel– carbo –bev with maintenance in patients 
with lung cancer has been performed. Mean total costs per 
patient per month were significantly lower for pemetrexed–
platinum patients compared to paclitaxel– carbo –bev patients 
in the setting of first-line treatment to progression in lung 
cancer patients with commercial or Medicare supplemental 
health insurance.57
Conflicting retrospective data have been generated about 
efficacy and safety of bev in elderly patients with NSCLC. 
The elderly subset analysis of the ECOG 4599 study showed 
no statistically significant improvement in ORR, PFS, or OS 
in 224 patients aged ≥70 years (26% of cases). Grade III–IV 
AEs were significantly more frequent in the elderly subjects 
compared with the younger subjects (87% vs 61%).58 In 
contrast, in the retrospective analysis performed on 304 
elderly patients aged ≥65 years, out of a total of 1,430 
patients enrolled in the AVAiL study, improved PFS, with 
no impact on survival and no significant toxicities, has been 
documented, as in the younger patients.59
Similarly, no significant difference was shown in rates of 
OS, PFS, and overall AEs among older and younger patient 
subsets in the SAiL and ARIES studies, with the exception of 
lower survival rates in patients aged 80 years or above vs those 
below 80 years of age.31,60 Moreover, a recent Phase II study 
has documented the good safety and efficacy of carbo plus 
weekly paclitaxel with bev as first-line regimen for elderly 
NSCLC patients.61 It is possible that the following factors 
have led to this heterogeneity of results: a higher median age 
for the ECOG 4599 cases than the other abovementioned 
studies; difficulty in distinguishing between side effects 
caused by bev (such as hypertension and proteinuria) and 
complications associated with the disease and/or age; and 
increased attention by clinicians to the side effects of bev, 
with better management in the most recent studies.62
Currently, there are no validated predictive biomarkers of 
response to treatment with bev according to which it could be 
possible to select patients with nonsquamous NSCLC with-
out targetable molecular abnormality.63 Potential biomark-
ers could be circulating levels of short VEGF-A isoforms, 
expression of neuropilin-1 and VEGFR-1 in tumors and 
plasma, genetic variants in VEGF-A and VEGFR, and TP53 
mutations (which are associated with increased VEGF-A 
transcript levels).64 Several recent studies suggest that these 
biomarkers could correlate with better clinical outcomes in 
NSCLC patients treated with antiangiogenesis agents.65–68 
These preliminary interesting results merit an additional 
investigation. Therefore, currently the eligibility for bev in 
NSCLC is based solely on clinical and histopathological 
features.
Future clinical developments of bev in NSCLC treatment 
could include its combination with immunotherapy. This 
novel approach could have a synergistic effect and enhance 
the efficacy of both treatments, according to preclinical 
growing evidence that proangiogenic factors modulate the 
immune response (both by reducing T-cell infiltration into 
the tumor microenvironment and through systemic effects 
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Moreover, recent studies have documented that contin-
ued VEGF suppression with bev beyond progression on the 
first-line therapy in patients with nonsquamous NSCLC led 
to more favorable clinical outcomes when this agent is com-
bined with second-line chemotherapy; positive results have 
been demonstrated also for bev plus pemetrexed maintenance 
after first-line chemotherapy with bev, carbo, and pemetrexed. 
Further well-conducted, large-scale trials are needed to vali-
date these findings. Last, results of trials on efficacy of the 
addition of bev to adjuvant chemotherapy in patients with 
completely resected stage IB–IIIA NSCLC and results con-
cerning benefit of first-line combination of erlotinib plus bev 
instead of erlotinib alone, in patients with NSCL, harboring 
activating EGFR mutations are still ongoing.
Cellular microRNAs (miRNAs) regulate gene expression 
through modulation of messenger RNA transcription and 
are involved in epigenetic regulation, metastasis, and cancer 
immunity. Recently, Huang et al71 have evaluated the changes 
in microRNA profile in lung cancer cell treated with cis and 
pemetrexed or pemetrexed–ciaplatin with bev. There is a 
difference of the miRNA profile in these 2 treatment groups 
suggesting that they may influence the regulation of miRNA, 
which could be involved in the activity of chemotherapy and 
development of resistance.
Combretastatin A4-phosphate, fosbretabulin trometh-
amine, is a vascular disrupting agent that targets tumor vas-
culature. Combretastatin A4-phosphate plus carbo, paclitaxel, 
and bev appears to be a tolerable regimen with an acceptable 
toxicity profile in subjects with advanced NSCLC.72
In nonsquamous NSCLC, the efficacy of combination 
of first-line chemotherapy with onartuzumab, a monova-
lent monoclonal antibody that binds with the extracellular 
domain of the MET receptor, has been investigated. Patients 
with untreated stage IIIB/IV nonsquamous NSCLC, strati-
fied by MET diagnostic status, were randomized to receive 
onartuzumab (15 mg/kg intravenously every 3 weeks) or 
placebo in combination with either paclitaxel/platinum/bev 
(bev cohort), or in combination with platinum/pemetrexed 
(pemetrexed cohort) with maintenance bev or pemetrexed 
and onartuzumab/placebo as appropriate. The results of this 
Phase II study were negative: onartuzumab does not appear to 
provide any additional clinical benefit when given in combi-
nation with current first-line standard-of-care chemotherapy 
for nonsquamous NSCLC.73
Patents for bev will soon expire in Europe and the US, 
and several bev biosimilars are in development.74 A physi-
cian survey examined barriers to the access of bev in patients 
with advanced solid tumors and the potential impact of 
 biosimilars. Lack of reimbursement and high out-of-pocket 
costs were cited as predominant barriers to prescribing and as 
common reasons for reducing the number of planned cycles. 
Overall, ~50% of physicians reported they “definitely” or 
“probably” would prescribe a bev biosimilar, if available. 
Efficacy and safety data in specific tumor types and lower 
cost were factors cited that would increase likelihood to 
prescribe a bev biosimilar.75
Conclusion
bev has led to improved clinical outcomes when added to 
standard first-line chemotherapy in patients with advanced 
or recurrent nonsquamous NSCLC without targetable 
molecular abnormality. Innovative combinations of bev and 
its maintenance beyond disease progression in NSCLC are 
currently under study.
Eligibility for bev is not affected by patient age, 
performance status, anticoagulation therapy, and brain 
metastases. The only absolute contraindications to its use 
are squamous histology and a history of clinically signifi-
cant hemoptysis. There are as yet no validated predictive 
biomarkers of response to treatment with antiangiogenic 
therapy. Therefore, there is the need for additional trans-
lational research to identify those patients who can really 
benefit from the use of bev, through the identification of 
specific response markers.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J 
Clin. 2010;60(5):277–300.
2. Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemo-
therapy in advanced non small cell lung cancer: a systematic review 
and meta-analysis. Plos One. 2011;6(8):e22681.
3. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of 
nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with 
advanced, refractory squamous non-small-cell lung cancer (CheckMate 
063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265.
4. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel 
in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 
2015;373:123–135.
5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel 
in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 
2015;373:1627–1639.
6. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel 
for previously treated, PD-L1-positive, advanced non-small-cell lung 
cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 
2016;387:1540–1550
7. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus 
docetaxel for patients with previously treated non-small-cell lung cancer 




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





8. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab 
versus chemotherapy for PD-L1-positive non-small-cell lung cancer. 
N Engl J Med. 2016;375:1823–1833.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J 
Med. 1971;285(21):1182–1186.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. 
Cell. 2011;144:646–674.
11. Ferrara N. Vascular endothelial growth factor as a target for anticancer 
therapy. Oncologist. 2004;9(Suppl 1):2–10.
12. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the 
VEGF-specific antibody bevacizumab has antivascular effects in human 
rectal cancer. Nat Med. 2004;10(2):145–147.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or 
with bevacizumab for non-small cell lung cancer. N Engl J Med. 
2006;355(24):2542–2550.
14. Folkman J. What is the evidence that tumors are angiogenesis depen-
dent? J Natl Cancer Inst. 1990;82:4–6.
15. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncol-
ogy. 2005;69(Suppl 3):4–10.
16. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of 
angiogenesis. Cell. 2011;146(6):873–887.
17. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of 
stimulators and inhibitors. Thromb Haemost. 1997;78(1):672–677.
18. Daniel TO, Abrahamson D. Endothelial signal integration in vascular 
assembly. Annu Rev Physiol. 2000;62:649–671.
19. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present 
in invasive human breast carcinomas promote tumor growth and 
angiogenesis through elevated SDF-1/ CXCL12 secretion. Cell. 
2005;121(3):335–348.
20. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its recep-
tors. Nat Med. 2003;9(6):669–676.
21. Shikada Y, Yonemitsu Y, Koga T, et al. Platelet-derived growth factor-AA is 
an essential and autocrine regulator of vascular endothelial growth factor 
expression in non-small cell lung carcinomas. Cancer Res. 2005;65(16): 
7241–7248.
22. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al. Vascular endo-
thelial growth factor/KDR activated microvessel density versus CD31 
standard microvessel density in non-small cell lung cancer. Cancer Res. 
2000;60(11):3088–3095.
23. O’Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular 
endothelial growth factor, platelet-derived endothelial cell growth 
factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 
2000;82(8):1427–1432.
24. Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vas-
cular endothelial growth factor-C and vascular endothelial growth 
factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 
2005;104(8):1668–1677.
25. Takizawa H, Kondo K, Fujino H, et al. The balance of VEGF-C and 
VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small 
cell lung cancer. Br J Cancer. 2006;95(1):75–79.
26. Chen ZJ, Le HB, Zhang YK, Qian LY, Li WD. Microvessel density 
and expression of thrombospondin-1 in non-small cell lung cancer 
and their correlation with clinicopathological features. J Int Med Res. 
2009;37(2):551–556.
27. Devery AM, Wadekar R, Bokobza SM, Weber AM, Jiang Y, Ryan AJ. 
Vascular endothelial growth factor directly stimulates tumour cell prolif-
eration in non-small cell lung cancer. Int J Oncol. 2015;47(3):849–856.
28. Reck M, Von Pavel J, Zatloukal P, et al. Phase III trial of cisplatin plus 
gemcitabine with either placebo or bevacizumab as first-line therapy 
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol. 
2009;27(8):1227–1234.
29. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-
gemcitabine and bevacizumab or placebo as first-line therapy for non-
squamous non-small-cell lung cancer: results from a randomised phase 
III trial (AVAiL). Ann Oncol. 2010;21(9):1804–1809.
30. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: random-
ized, open-label, phase III study of first-line pemetrexed + carboplatin 
followed by maintenance pemetrexed versus paclitaxel + carboplatin 
+ bevacizumab followed by maintenance bevacizumab in patients with 
advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 
2015;10(1):134–142.
31. Patel JD, Socinski MA, Garon EB, et al. A randomized phase III study 
of pemetrexed plus carboplatin and bevacizumab followed by mainte-
nance pemetrexed and bevacizumab versus paclitaxel plus carboplatin 
and bevacizumab followed by maintenance bevacizumab in patients 
with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin 
Oncol. 2013;31(34):4349–4357.
32. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial 
of maintenance bevacizumab with or without pemetrexed after first-line 
induction with bevacizumab, cisplatin, and pemetrexed in advanced 
nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). 
J Clin Oncol. 2013;31(24):3004–3011.
33. Schneider BJ, Kalemkerian GP, Gadgeel SM, et al. Phase II trial of dose-
dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced, 
non-small-cell lung cancer. Clin Lung Cancer. 2017;18(3):299–302.
34. Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevaci-
zumab treatment to progression after chemotherapy: outcomes from a 
U.S. community practice network. Oncologist. 2011;16(4):486–496.
35. Gridelli C, Bennouna J, de Castro J, et al. Randomized phase IIIb trial 
evaluating the continuation of bevacizumab beyond disease progression 
in patients with advanced non-squamous non-small-cell lung cancer 
after first-line treatment with bevacizumab plus platinum-based che-
motherapy: treatment rationale and protocol dynamics of the AvaALL 
(MO22097) trial. Clin Lung Cancer. 2011;12(6):407–411.
36. A phase III randomized trial of adjuvant chemotherapy with or without 
bevacizumab for patients with completely resected stage IB (≥ 4 cm) 
- IIIA Non-small Cell Lung Cancer (NSCLC). Available from: https://
clinicaltrials.gov/ct2/show/NCT00324805. Accessed February 7, 2017.
37. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab 
as first-line therapy in patients with advanced non-squamous non-
small-cell lung cancer harbouring EGFR mutations (JO25567): an 
open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 
2014;15:1236–1244.
38. An open-label phase II trial of erlotinib and bevacizumab in patients 
with advanced non-small cell lung cancer and activating EGFR muta-
tions. Available from: https://clinicaltrials.gov/ct2/show/NCT01562028. 
Accessed July 29, 2017.
39. Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: random-
ized, double-blind, placebo-controlled, phase IIIB trial comparing 
bevacizumab therapy with or without erlotinib, after completion of 
chemotherapy, with bevacizumab for first-line treatment of advanced 
non-small-cell lung cancer. J Clin Oncol. 2013;31(31):3926–3934.
40. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus 
erlotinib versus erlotinib alone in advanced non-small-cell lung cancer 
after failure of standard first-line chemotherapy (BeTa): a double-blind, 
placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–1854.
41. A randomized open-label phase 3 trial comparing bevacizumab + 
erlotinib vs erlotinib alone as first line treatment of patients with EGFR 
mutated advanced non squamous non small cell lung cancer. Available 
from: https://clinicaltrials.gov/ct2/show/NCT02633189. Accessed 
February 7, 2017.
42. Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line 
bevacizumab-based therapy in advanced non-squamous non-small 
cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 
2010;11(8):733–740.
43. Fishbach NA, Spigel D, Brahmer J, et al; ARIES investigators. Prelimi-
nary safety and effectiveness of bevacizumab (Bv)-based treatment in 
subpopulation of patients (pts) with non-small cell lung cancer (NSCLC) 
from the ARIES study: a bevacizumab Bv treatment observational 



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





44. Polikoff J, Hainsworth JD, Fehrenbacher L, et al. Safety of bevacizumab 
(Bv) therapy in combination with chemotherapy in subjects with non 
small cell lung cancer (NSCLC) treated on ATLAS. J Clin Oncol. 
2008;26(15S):Abstract 8079.
45. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in 
patients with non-small cell lung cancer and brain metastases. J Clin 
Oncol. 2009;27(31):5255–5261.
46. Matikas A, Kentepozidis Ν, Ardavanis A, et al. Efficacy and tolerance 
of frontline bevacizumab-based chemotherapy for advanced non-small 
cell lung cancer patients: a multicenter, phase IV study of the Hellenic 
Oncology Research Group (HORG). Cancer Chemother Pharmacol. 
2016;78(2):369–376.
47. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise 
following angiogenesis inhibition by bevacizumab. A crucial role for 
microcirculation. Ann Oncol. 2008;19(5):927–934.
48. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates 
ecNOS message, protein, and NO production in human endothelial 
cells. Am J Physiol. 1998;274(3 Pt 2):H1054–H1058.
49. Takagi Y, Toriihara A, Nakahara Y, et al. Eligibility for bevacizumab 
as an independent prognostic factor for patients with advanced non-
squamous non-small cell lung cancer: a retrospective cohort study. 
PLoS One. 2013;8(3):e59700.
50. Reck M, Barlesi F, Crinò L, et al. Predicting and managing the risk 
of pulmonary haemorrhage in patients with NSCLC treated with 
bevacizumab: a consensus report from a panel of experts. Ann Oncol. 
2012;23(5):1111–1120.
51. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the 
clinical and radiographic risk factors associated with severe pulmonary 
hemorrhage in first-line advanced, unresectable non-small-cell lung 
cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin 
Oncol. 2009;27:1405–1412.
52. Griesinger F, Bearz A, Eberhardt W, et al. Safety of first-line bevaci-
zumab (BV)-based therapy in the sail (MO19390) trial: central tumour 
location (CTL) and hypertension (HTN) in patients (PTS) with advanced 
non-small cell lung cancer (NSCLC). Ann Oncol. 2010;21(Suppl 
8):viii144.
53. Barlesi F, Balleyguier C, Besse B, et al. Inter- and intraobserver consis-
tency in assessing eligibility for bevacizumab (BVZ) in non-small-cell 
lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol. 
2010;21:1682–1686.
54. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. 
Bevacizumab safety in patients with central nervous system metastases. 
Clin Cancer Res. 2010;16(1):269–278.
55. Lynch TJ Jr, Spigel DR, Brahmer J, et al. Safety and effectiveness of 
bevacizumab-containing treatment for non-small-cell lung cancer: 
final results of the ARIES observational cohort study. J Thorac Oncol. 
2014;9(9):1332–1339.
56. Stefanou D, Stamatopoulou S, Sakellaropoulou A, et al. Bevacizumab, 
pemetrexed and carboplatin in first-line treatment of non-small cell lung 
cancer patients: focus on patients with brain metastases. Oncol Lett. 
2016;12(6):4635–4642.
57. Sheffield KM, Winfree KB, Muehlenbein C, et al. MINI01.19: cost 
analysis of pemetrexed-platinum with maintenance vs. paclitaxel-
carboplatin-bevacizumab with maintenance in patients with lung 
cancer: topic: medical oncology. J Thorac Oncol. 2016;11(11S): 
S268.
58. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, 
advanced- stage non-small-cell lung cancer patients treated with 
bevacizumab in combination with carboplatin and paclitaxel: analy-
sis of eastern cooperative oncology group trial 4599. J Clin Oncol. 
2008;26(1):60–65.
59. Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of beva-
cizumab-based therapy in elderly patients with advanced or recurrent 
nonsquamous non-small cell lung cancer in the phase III BO17704 
study (AVAiL). J Thorac Oncol. 2010;5(12):1970–1976.
60. Laskin J, Crinò L, Felip E, et al. Safety and efficacy of first-line bevaci-
zumab plus chemotherapy in elderly patients with advanced or recurrent 
nonsquamous non-small cell lung cancer: safety of Avastin in lung trial 
(MO19390). J Thorac Oncol. 2012;7(1):203–211.
61. Miura S, Maemondo M, Iwashima A, et al. A phase II study of car-
boplatin plus weekly paclitaxel with bevacizumab for elderly patients 
with non-squamous non-small-cell lung cancer (NEJ016). Invest New 
Drugs. 2017;35(2):227–234. 
62. Antonelli G, Libra M, Panebianco V, et al. Molecular-targeted therapy 
for elderly patients with advanced non-small cell lung cancer. Oncol 
Lett. 2016;11(1):3–8.
63. Duda DG, Ancukiewicz M, Jain RK. Biomarkers of antiangiogenic 
therapy: how do we move from candidate biomarkers to valid biomark-
ers? J Clin Oncol. 2010;28(2):183–185.
64. Kurzrock R, Stewart DJ. Exploring the benefit/risk associated with 
antiangiogenic agents for the treatment of non-small cell lung cancer 
patients. Clin Cancer Res. 2017;23(5):1137–1148.
65. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular 
endothelial growth factor, and basic fibroblast growth factor in patients 
with non-small cell lung cancer treated with chemotherapy with or 
without bevacizumab – an Eastern Cooperative Oncology Group Study. 
Clin Cancer Res. 2008;14(5):1407–1412.
66. Lambrechts D, Lenz HJ, de HS, Carmeliet P, Scherer SJ. Markers of 
response for the antiangiogenic agent bevacizumab. J Clin Oncol. 
2013;31(9):1219–1230.
67. Said R, Hong DS, Warneke CL, et al. P53 mutations in advanced 
cancers: clinical characteristics, outcomes, and correlation between 
progression-free survival and bevacizumab-containing therapy. Onco-
target. 2013;4(5):705–714.
68. Schwaederle M, Lazar V, Validire P, et al. VEGFA expression correlates 
with TP53 mutations in non-small cell lung cancer: implications for 
antiangiogenesis therapy. Cancer Res. 2015;75(7):1187–1190.
69. Manegold C, Dingemans AC, Gray JE, et al. The potential of combined 
immunotherapy and antiangiogenesis for the synergistic treatment of 
advanced NSCLC. J Thorac Oncol. 2017;12(2):194–207. 
70. Martino EC, Misso G, Pastina P, et al. Immune-modulating effects of 
bevacizumab in metastatic non-small-cell lung cancer patients. Cell 
Death Discov. 2016;2:16025.
71. Huang CH, Motes H, Sharma M, Reyes EB, Kevern J. PS01.33: change 
in microRNA profile in lung cancer cell treated with chemotherapy cis-
platin (C), pemetrexed (P) or PC with bevacizumab (B): topic: Medical 
oncology. J Thorac Oncol. 2016;11(11S):S289.
72. Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kab-
binavar F. A randomized Phase II trial of the tumor vascular disrupting 
agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, 
and bevacizumab in advanced nonsquamous non-small-cell lung cancer. 
Onco Targets Ther. 2016;9:7275–7283.
73. Wakelee H, Zvirbule Z, De Braud F, et al. Efficacy and safety of onartu-
zumab in combination with first-line bevacizumab- or pemetrexed-based 
chemotherapy regimens in advanced non-squamous non-small-cell lung 
cancer. Clin Lung Cancer. 2017;18(1):50–59.
74. Biosimilars of bevacizumab. Available from: http://www.gabionline.net/
Biosimilars/General/Biosimilars-of-bevacizumab. Accessed December 
9, 2016.
75. Monk BJ, Lammers PE, Cartwright T, Jacobs I. Barriers to the access of 
bevacizumab in patients with solid tumors and the potential impact of bio-



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Lung Cancer: Targets and Therapy 2017:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Lung Cancer: Targets and Therapy
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/lung-cancer-targets--therapy-journal
Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access 
journal focusing on lung cancer research, identification of therapeutic targets and 
the optimal use of preventative and integrated treatment interventions to achieve 
improved outcomes, enhanced survival and quality of life for the cancer patient. Spe-
cific topics covered in the journal include: Epidemiology, detection and screening; 
Cellular research and biomarkers; Identification of biotargets and agents with novel 
mechanisms of action; Optimal clinical use of existing anticancer agents, including 
combination therapies; Radiation and surgery; Palliative care; Patient adherence, 
quality of life, satisfaction; Health economic evaluations. The manuscript manage-
ment system is completely online and includes a very quick and fair peer-review 







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
© 2017. This work is licensed under
https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). 
Notwithstanding the ProQuest Terms and Conditions, you may use this content
in accordance with the terms of the License.
